FDA-cleared profile

SubtleMR (2.3.x)

Subtle Medical Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: MRI image enhancement by reducing image noise for head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal MRI, or increasing image sharpness for head MRI.

Clinical role
Post-acquisition image processing; the end user selects noise reduction or sharpness enhancement through the DICOM Series Description, a command-line argument, or an environment variable.
Images and patients
MRI · Head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal regions
Key limitation
Keep in mind: The device has no user interface and operates as a fixed nonlinear filter whose parameters depend on the selected enhancement. The packet establishes 1.2T, 1.5T, and 3T MRI inputs but does not identify scanner manufacturers, PACS compatibility, or a broader diagnostic-performance claim.

Overview status: Source-reviewed overview

Report a correction

Evaluation pilot

Before you shortlist

Exact FDA record: K223623 · Agent source review · . This is not clinician review or local acceptance.

Within this record's scope

  • Consider for noise reduction in the labeled MRI anatomies, or sharpness enhancement of head MRI, with the supported field strengths.

Limits to check

  • The reviewed record does not establish a named PACS pairing or a broader diagnostic-performance claim. Head sharpening and multi-anatomy denoising have different scope.

Questions for the vendor and your team

  1. Which release and enhancement functions are licensed, and how is the enhancement choice configured at this site?
  2. Can the team verify the image path, selected enhancement, output identity and small-structure visibility on representative local studies?

These questions are prompts for evaluation, not claims that licensing, compatibility, performance or price has been confirmed.

Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Image processing · source-reviewed 2026-11-09

Agent source review of original FDA labeling; not clinician sign-off or local workflow qualification.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: MRI image enhancement by reducing image noise for head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal MRI, or increasing image sharpness for head MRI.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal regions Input: Standard-of-care MRI images acquired on 1.2 Tesla, 1.5 Tesla, or 3 Tesla scanners; the subject device processes DICOM files and additionally can process images communicated over ISMRMRD raw-data format.
  • Who uses it?Intended users: Radiologists in an imaging center, clinic, or hospital.
  • What does the software produce?Output: MRI images with reduced noise or increased sharpness, with image quality changes evaluated through signal-to-noise ratio, small-structure visibility, anatomic-structure thickness, and boundary sharpness.
  • What is its most important limitation?Key limitation: The device has no user interface and operates as a fixed nonlinear filter whose parameters depend on the selected enhancement. The packet establishes 1.2T, 1.5T, and 3T MRI inputs but does not identify scanner manufacturers, PACS compatibility, or a broader diagnostic-performance claim.

Clinical takeaway. Clinical role: MRI image enhancement by reducing image noise for head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal MRI, or increasing image sharpness for head MRI.

Evidence takeaway. Evidence from the reviewed source record: FDA software verification and validation included a retrospective clinical-data study divided into noise-reduction and sharpness-enhancement tests. Noise reduction required average ROI signal-to-noise improvement of at least 5% and non-inferior small-structure visibility by Likert assessment; the test passed. Sharpness enhancement required improved anatomic-structure thickness and boundary sharpness in at least 90% of test datasets; the test passed. The packet text does not state the study sample sizes.

Evidence context: questions, not a score

Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.

K223623 · agent source review 2026-11-09 · exact submission

Existing study anchor: SubtleMR (2.3.x) regulatory performance study summary. Tested version label: Exact product version not reported; regulatory study summarized for FDA submission K223623.

What was tested?

Noise reduction and sharpness enhancement in retrospective MRI datasets, with software verification testing.

Source section: 510(k) summary, Non-Clinical and/or Clinical Tests Summary & Conclusions

On which cases and versions?

The reviewed FDA summary does not disclose the test sample size, site count, population composition or scanner-specific distribution. These are explicit unknowns, not zero.

Source section: 510(k) summary, Non-Clinical and/or Clinical Tests Summary & Conclusions

What changed?

The summary says both tests passed. Mean ROI SNR improvement of at least 5% and sharpness criteria in at least 90% of test datasets are acceptance criteria, not reported average clinical-effect magnitudes.

Source section: 510(k) summary, Non-Clinical and/or Clinical Tests Summary & Conclusions

What does this not establish?

Passed image-quality criteria do not establish cancer-detection sensitivity, patient outcomes, net throughput or performance for every MRI protocol. Missing sample sizes and confidence intervals remain missing.

Source section: 510(k) summary, Non-Clinical and/or Clinical Tests Summary & Conclusions

Study design, population and missing context
evidence Role
Retrospective image-enhancement testing for noise reduction and sharpness; separate software verification.

technical validation · 510(k) summary, Non-Clinical and/or Clinical Tests Summary & Conclusions

design
Retrospective clinical images evaluated in noise-reduction and sharpness-enhancement tests; methods described as identical to the predicate.

technical validation · 510(k) summary, Non-Clinical and/or Clinical Tests Summary & Conclusions

setting
Not established: The reviewed regulatory summary does not establish this field for this study context.
training Population
Not established: The reviewed regulatory summary does not establish this field for this study context.
evaluation Population
Retrospective MRI datasets; exact sample size and subgroup counts not disclosed in the reviewed summary.

technical validation · 510(k) summary, Non-Clinical and/or Clinical Tests Summary & Conclusions

reference Standard
Not established: The reviewed regulatory summary does not establish this field for this study context.
comparator
Enhanced versus original images for SNR, small-structure visibility and sharpness criteria.

technical validation · 510(k) summary, Non-Clinical and/or Clinical Tests Summary & Conclusions

sites
Not established: The reviewed regulatory summary does not establish this field for this study context.
scanner Protocol
Not established: The reviewed regulatory summary does not establish this field for this study context.
sample Composition
Not established: The reviewed regulatory summary does not establish this field for this study context.
sponsor Involvement
Subtle Medical conducted the testing described in the regulatory summary.

regulatory summary · 510(k) summary, Non-Clinical and/or Clinical Tests Summary & Conclusions

Public-label constraints

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Exact FDA submission K223623 · agent source review 2026-11-09 · SubtleMR (2.3.x)

Authorized population

Not established: No explicit constraint transcribed from the reviewed labeling sections. Unknown does not mean unrestricted.

Label age limits

Not established: No numerical age bound or explicit all-ages statement in the reviewed labeling sections. Study ages do not establish authorized age limits.

Documented care setting

Imaging center, clinic or hospital; intended for radiologists.

Modality and protocol

MRI image enhancement: noise reduction in head, spine, neck, abdomen, pelvis, prostate, breast and musculoskeletal MRI; sharpness enhancement for head MRI.

Labeled anatomy

Noise reduction: head, spine, neck, abdomen, pelvis, prostate, breast and musculoskeletal. Sharpness enhancement: head.

Acquisition constraints

Description specifies MRI exams acquired on 1.2 T, 1.5 T or 3 T scanners. Noise reduction and sharpness enhancement are separate choices.

Exclusions and human review

The reviewed indication limits sharpness enhancement to head MRI; the other listed anatomies are for noise reduction.

Purpose
MRI image enhancement by reducing image noise for head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal MRI, or increasing image sharpness for head MRI.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Post-acquisition image processing; the end user selects noise reduction or sharpness enhancement through the DICOM Series Description, a command-line argument, or an environment variable.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Standard-of-care MRI images acquired on 1.2 Tesla, 1.5 Tesla, or 3 Tesla scanners; the subject device processes DICOM files and additionally can process images communicated over ISMRMRD raw-data format.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
MRI images with reduced noise or increased sharpness, with image quality changes evaluated through signal-to-noise ratio, small-structure visibility, anatomic-structure thickness, and boundary sharpness.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Imaging center, clinic, or hospital MRI workflow.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Radiologists in an imaging center, clinic, or hospital.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
The device has no user interface and operates as a fixed nonlinear filter whose parameters depend on the selected enhancement. The packet establishes 1.2T, 1.5T, and 3T MRI inputs but does not identify scanner manufacturers, PACS compatibility, or a broader diagnostic-performance claim.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA software verification and validation included a retrospective clinical-data study divided into noise-reduction and sharpness-enhancement tests. Noise reduction required average ROI signal-to-noise improvement of at least 5% and non-inferior small-structure visibility by Likert assessment; the test passed. Sharpness enhancement required improved anatomic-structure thickness and boundary sharpness in at least 90% of test datasets; the test passed. The packet text does not state the study sample sizes.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA software verification and validation included a retrospective clinical-data study divided into noise-reduction and sharpness-enhancement tests. Noise reduction required average ROI signal-to-noise improvement of at least 5% and non-inferior small-structure visibility by Likert assessment; the test passed. Sharpness enhancement required improved anatomic-structure thickness and boundary sharpness in at least 90% of test datasets; the test passed. The packet text does not state the study sample sizes.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

SubtleMR (2.3.x) regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K223623
  • IndependenceIndependence not established

K223623

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K223623. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

ISMRMRD input interface

Conditional support

  • AI version: SubtleMR (2.3.x); system version: not established
  • Scope: exact submission; geography: United States labeling
  • Configuration: The reviewed SubtleMR release can process images communicated over ISMRMRD; a format-version pairing is not established.
  • Condition: Agree the exact sender, format version, enhancement choice and supported data path.
  • Local test needed: Check identifiers, geometry, image identity, enhancement output, latency and recovery using representative site data.
  • Source review: 2026-11-06
  • Source documentation describes this scope; local installed-system acceptance remains open.
  • Installed-system acceptance has not been performed.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

Existing route context (at most two)

Scanner/input support
  • Conditional support
  • AI version: SubtleMR (2.3.x); system version: not established
  • Scope: exact submission; geography: United States labeling
  • Configuration: The reviewed SubtleMR release can process images communicated over ISMRMRD; a format-version pairing is not established.
  • Condition: Agree the exact sender, format version, enhancement choice and supported data path.
  • Local test needed: Check identifiers, geometry, image identity, enhancement output, latency and recovery using representative site data.
  • Source review: 2026-11-06
  • Source documentation describes this scope; local installed-system acceptance remains open.
  • Installed-system acceptance has not been performed.

FDA K223623: SubtleMR (2.3.x)

  1. Acquisition/source

    Source context, not route validation: Standard-of-care MRI images acquired on 1.2 Tesla, 1.5 Tesla, or 3 Tesla scanners; the subject device processes DICOM files and additionally can process images communicated over ISMRMRD raw-data format.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K223623: SubtleMR (2.3.x)

  2. Routing

    Source context, not route validation: The FDA packet describes operation on DICOM files on a file system, storage of enhanced images on the file system, and additional ISMRMRD raw-data processing; it does not establish PACS, RIS, EHR, interface-version, or local compatibility.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K223623: SubtleMR (2.3.x)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-09 ·

  4. Returned objects

    Source context, not route validation: MRI images with reduced noise or increased sharpness, with image quality changes evaluated through signal-to-noise ratio, small-structure visibility, anatomic-structure thickness, and boundary sharpness.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K223623: SubtleMR (2.3.x)

  5. Viewer/worklist/report

    Unresolved route: MRI images with reduced noise or increased sharpness, with image quality changes evaluated through signal-to-noise ratio, small-structure visibility, anatomic-structure thickness, and boundary sharpness.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K223623: SubtleMR (2.3.x)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA packet describes operation on DICOM files on a file system, storage of enhanced images on the file system, and additional ISMRMRD raw-data processing; it does not establish PACS, RIS, EHR, interface-version, or local compatibility.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Subtle Medical's compliance page lists annual SOC 2 Type II + HIPAA security audits and independent certifications including EN ISO 13485:2016 (with MDSAP) and ISO/IEC 42001:2023 (AI management systems), with stated validity dates.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statements; audit reports and certificates not read. SubtleMR is now branded SubtleHD (MR) on the vendor site. Exact-release scope is not established.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for SubtleMR (2.3.x); FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223623
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Head, spine, neck, abdomen, pelvis, prostate, breast, and musculoskeletal regions
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-05-11
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Documented product family

Related FDA records

These links identify a sourced product-family relationship. They do not transfer evidence, metrics, clearance scope, compatibility, pricing, or availability between submissions.

SubtleMR image enhancement

Open the documented family

A partial mapping of two reviewed FDA submissions. Evidence, compatible inputs, licensing and availability remain specific to each record.

The K223623 summary identifies SubtleMR K203182 as the predicate and describes changes to the same image-enhancement software.

Mapped FDA decisions, earliest first

Latest mapped does not mean latest sold or installed. Choose an exact FDA record before comparing.

  1. Related FDA recordSubtleMR (K203182)

    SubtleMR V2.0.0

    FDA decision: 2021-02-26 · record reviewed 2026-11-09
  2. This FDA recordSubtleMR (2.3.x) (K223623)

    SubtleMR 2.3.x

    Latest mapped FDA decisionFDA decision: 2023-05-11 · record reviewed 2026-11-09

Documented names and scope

  • SubtleMR V2.0.0 · K203182. Name for this exact FDA record, not an alias for every commercial configuration. Name source
  • SubtleMR 2.3.x · K223623. Name for this exact FDA record, not an alias for every commercial configuration. Name source

SubtleMR image enhancement

MRI noise reduction and head-image sharpness enhancement. Applies to K203182, K223623. This describes the mapped function only; feature parity and a shared license are not established.

Availability evidence, separate from FDA decisions

  • not established

    Current availability of an exact FDA-submission configuration is not established. Ask the supplier for the offered release and licensed modules.

  • historical statement · SubtleMR 2.0 · United States announcement; exact local supply not established · statement dated 2021-03-10

    Historical vendor announcement of second-generation release and commercial use. Not a current availability or exact-submission license assertion.

    Availability source
Latest FDA decision among these records
K223623 · 2023-05-11. Latest mapped decision only. Not automatically the latest sold or installed version, and not a supersession claim.
Latest documented release
Current commercial release or exact offered configuration is not established by this partial mapping.
Current commercial availability
Current commercial release or exact offered configuration is not established by this partial mapping.

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
9Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K223623 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-09 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

11 sources - 3 history items

Source ledger

  1. FDA K223623: SubtleMR (2.3.x)

    U.S. Food and Drug Administration - Published 2023-05-11 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. SubtleMR (2.3.x) model card (K223623)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K223623

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Subtle Medical: Compliance

    Subtle Medical - Accessed 2026-10-27

    Scope: security

  9. FDA decision summary for K203182 - SubtleMR

    U.S. Food and Drug Administration - Published 2021-02-26 - Accessed 2026-11-09

    Scope: regulatoryIdentity, productIdentity, indication, modality, anatomy, workflowRole, input, output, limitations, evidenceSummary, product_family

  10. FDA K223623: SubtleMR (2.3.x)

    U.S. Food and Drug Administration - Published 2023-05-11 - Accessed 2026-11-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, product_family

  11. SubtleMR 2.0 launch

    Subtle Medical - Published 2021-03-10 - Accessed 2026-11-09

    Scope: product_family

Research history

  1. K223623 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253780

SIGNA™ Bolt

Ge Medical Systems, LLC

Authorized purpose: SIGNA Bolt is a whole-body MRI system for high-resolution diagnostic imaging of the labeled body regions, with supported AI-assisted reconstruction, positioning, and protocol functions.

Modality
MRI
Anatomy
Head, neck, temporomandibular joint, spine, breast, heart, abdomen, pelvis, joints, prostate, vessels, and musculoskeletal anatomy
Decision
2026-02-06
FDA-cleared K253779

SIGNA™ Sprint Select

Ge Medical Systems, LLC

Authorized purpose: SIGNA Sprint Select is a whole-body MRI system for diagnostic imaging of the labeled body regions, with supported AI-assisted reconstruction, positioning, and protocol functions.

Modality
MRI
Anatomy
Head, neck, temporomandibular joint, spine, breast, heart, abdomen, pelvis, joints, prostate, vessels, and musculoskeletal anatomy
Decision
2026-02-05
FDA-cleared K251399

SIGNA™ Sprint

GE Medical Systems, LLC

Authorized purpose: SIGNA Sprint is a 1.5T whole-body MRI system for diagnostic imaging of the labeled head, neck, TMJ, spine, breast, heart, abdomen, pelvis, joints, prostate, vessels, and musculoskeletal regions.

Modality
MRI
Anatomy
Head; neck; temporomandibular joint; spine; breast; heart; abdomen; pelvis; joints; prostate; vessels; and musculoskeletal anatomy
Decision
2025-09-11
FDA-cleared K250379

SIGNA Prime Elite

GE Medical Systems, LLC

Authorized purpose: SIGNA Prime Elite is a whole-body MR system that produces cross-sectional, spectroscopic, parametric, and dynamic images of the labeled body regions for trained physician interpretation, with contrast use depending on the region and protocol.

Modality
MRI
Anatomy
Head, neck, temporomandibular joint, spine, breast, heart, abdomen, pelvis, joints, prostate, vessels, and musculoskeletal anatomy
Decision
2025-03-17

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history